Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer

Anticancer Res. 2001 Jan-Feb;21(1A):409-12.


The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.

Publication types

  • Comparative Study

MeSH terms

  • Alpha Particles / therapeutic use
  • Animals
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Astatine / therapeutic use*
  • Beta Particles / therapeutic use
  • Bone Marrow / radiation effects
  • Cell Division / radiation effects
  • Female
  • Humans
  • Immunoconjugates / pharmacokinetics
  • Immunoconjugates / therapeutic use*
  • Iodine Radioisotopes / therapeutic use
  • Mice
  • Mice, Nude
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / radiotherapy*
  • Peritoneal Neoplasms / metabolism
  • Peritoneal Neoplasms / radiotherapy*
  • Peritoneal Neoplasms / secondary
  • Radioimmunotherapy*
  • Radiotherapy Dosage
  • Tumor Cells, Cultured


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoconjugates
  • Iodine Radioisotopes
  • MOv18 monoclonal antibody
  • Astatine